2024
Casein kinase 1 inhibitor avoids TDP-43 pathology propagation in a patient-derived cellular model of amyotrophic lateral sclerosis. Cuevas EP, Martinez-Gonzalez L, Gordillo C, Tosat-Bitrián C, Pérez de la Lastra C, Sáenz A, Gil C, Palomo V, Martin-Requero Á, Martinez A.Neurobiol Dis. 2024 Mar;192:106430. https://doi.org/10.1016/j.nbd.2024.106430
Efficacy of a benzothiazole‐based LRRK2 inhibitor in oligodendrocyte precursor cells and in a murine model of multiple sclerosis. Benítez-Fernández R, Josa-Prado F, Sánchez E, Lao Y, García-Rubia A, Cumella J, Martínez A, Palomo V, de Castro F (2024) CNS Neuroscience. 30, 1755-5949. https://doi.org/10.1111/cns.14552
2023
TTBK1 and CK1 inhibitors restore TDP-43 pathology and avoid disease propagation in lymphoblast from Alzheimer's disease patients. Martinez-Gonzalez L, Cuevas EP, Tosat-Bitrián C, Nozal V, Gil C, Palomo V, Martín-Requero Á, Martinez A.Front Mol Neurosci. 2023 Aug 9;16:1243277. https://doi.org/10.3389/fnmol.2023.1243277
The key role of TDP-43 in amyotrophic lateral sclerosis propagation and the disease-modifying profile of CK-1 inhibitors. P. Cuevas E, Martínez-Gonzalez L, Gordillo C, Tosat C, Pérez de la Lastra C, Sáez A, Gil C, Palomo V, Martin-Requero A, Martinez A. (2023) Research Square https://doi.org/10.21203/rs.3.rs-3327624/v1
Nanomedical research and development in Spain: improving the treatment of diseases from the nanoscale. Fernández P, Pérez de la Lastra C, Tosat-Bitrian C, Bueso de Barrio JA, Thompson S, Sot B, Salas G, Somoza A, Espinosa A, Castellanos M, Palomo V. (2023) Frontiers in Bioengineering and Biotechnology 11, 2296-4185 https://doi.org/10.3389/fbioe.2023.1191327
PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer’s Disease. M Guardigni, L Pruccoli, A Santini, AD Simone, M Bersani, F Spyrakis, F Frabetti, E Uliassi, V Andrisano, B Pagliarani, P Fernández-Gómez, V Palomo, ML Bolognesi, A Tarozzi, and A Milelli. (2023) ACS Chem Neurosci. 14, 1963–1970. https://doi.org/10.1021/acschemneuro.3c00096
Neurodegeneration, cell signaling and neuroreparative strategies, Volume II. AR Vaz, AS Falcão, V Palomo. (2023) Front in Pharmacol. 14, 1198151. https://doi.org/10.3389/fphar.2023.1198151
Evaluating the Catalytic Efficiency of the Human Membrane-type 1 Matrix Metalloproteinase (MMP-14) Using AuNP-Peptide Conjugates. Jin Z, Dridi N, Palui G, Palomo V, Jokerst JV, Dawson PE, Amy Sang QX, Mattoussi H. (2023) J Am Chem Soc. 145, 4570-4582. https://doi.org/10.1021/jacs.2c12032
Quantum Dot-Peptide Conjugates as Energy Transfer Probes for Sensing the Proteolytic Activity of Matrix Metalloproteinase-14. Jin Z, Dridi N, Palui G, Palomo V, Jokerst JV, Dawson PE, Sang QA, Mattoussi H. (2023) Anal Chem. 95, 2713-2722. https://doi.org/10.1021/acs.analchem.2c03400
2022
Editorial: Neurodegeneration, cell signaling and neuroreparative strategies. Vaz AR, Falcão AS, Palomo V. (2022) Front Pharmacol. 13, 1059923.https://doi.org/10.3389/fphar.2022.1059923
Effect of Clinically Used Microtubule Targeting Drugs on Viral Infection and Transport Function. Oliva MÁ, Tosat-Bitrián C, Barrado-Gil L, Bonato F, Galindo I, Garaigorta U, Álvarez-Bernad B, París-Ogáyar R, Lucena-Agell D, Giménez-Abián JF, García-Dorival I, Urquiza J, Gastaminza P, Díaz JF, Palomo V*, Alonso C*. (2022) Int J Mol Sci. 23, 3448. https://doi.org/10.3390/ijms23073448
TDP-43 Pathology and Prionic Behavior in Human Cellular Models of Alzheimer's Disease Patients. Cuevas EP, Rodríguez-Fernández A, Palomo V, Martínez A, Martín-Requero Á. (2022) Biomedicines.10, 385. https://doi.org/10.3390/biomedicines10020385
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Nozal V, Martínez-González L, Gomez-Almeria M, Gonzalo-Consuegra C, Santana P, Chaikuad A, Pérez-Cuevas E, Knapp S, Lietha D, Ramírez D, Petralla S, Monti B, Gil C, Martín-Requero A, Palomo V, de Lago E, Martinez A. (2022) J Med Chem. 65, 1585-1607. https://doi.org/10.1021/acs.jmedchem
2021
Allosteric Modulation of GSK-3β as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. Rico, A., Guembelzu, G., Palomo, V., Martínez, A., Aiastui, A., Casas-Fraile, L., Valls, A., López de Munain, A., & Sáenz, A. (2021). International journal of molecular sciences, 22, 7367. cdoi.org/10.3390/ijms22147367
From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis. Nozal, V., García-Rubia, A., Cuevas, E. P., Pérez, C., Tosat-Bitrián, C., Bartolomé, F., Carro, E., Ramírez, D., Palomo, V., & Martínez, A. (2021). Angewandte Chemie , 60, 19344–19354. https://doi.org/10.1002/anie.202106295
CdSe Quantum Dots in Human Models Derived from ALS Patients: Characterization, Nuclear Penetration Studies and Multiplexing. Tosat-Bitrián, C., Avis-Bodas, A., Porras, G., Borrego-Hernández, D., García-Redondo, A., Martín-Requero, A., & Palomo, V. (2021). Nanomaterials, 11, 671. https://doi.org/10.3390/nano11030671
CdSe quantum dots evaluation in primary cellular models or tissues derived from patients. Tosat-Bitrián, C., & Palomo, V. (2020). Nanomedicine: nanotechnology, biology, and medicine, 30, 102299. https://doi.org/10.1016/j.nano.2020.102299
Palomo, V., Nozal, V., Rojas-Prats, E., Gil, C., & Martinez, A. (2021).. British journal of pharmacology, 178(6), 1316–1335. https://doi.org/10.1111/bph.15221
2019
Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. Palomo, V., Tosat-Bitrian, C., Nozal, V., Nagaraj, S., Martin-Requero, A., & Martinez, A. (2019). TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. ACS chemical neuroscience, 10(3), 1183–1196. https://doi.org/10.1021/acschemneuro.9b00026
2018
Efficient Assembly of Quantum Dots with Homogenous Glycans Derived from Natural N-Linked Glycoproteins. Palomo, V., Cistrone, P. A., Zhan, N., Palui, G., Mattoussi, H., & Dawson, P. E. (2018). Bioconjugate chemistry, 29, 3144–3153. https://doi.org/10.1021/acs.bioconjchem.8b00477
Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. Sánchez-Cruz, A., Villarejo-Zori, B., Marchena, M., Zaldivar-Díez, J., Palomo, V., Gil, C., Lizasoain, I., de la Villa, P., Martínez, A., de la Rosa, E. J., & Hernández-Sánchez, C. (2018). Molecular neurodegeneration, 13(1), 19. https://doi.org/10.1186/s13024-018-0251-y
2017
Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Palomo, V., Perez, D. I., Roca, C., Anderson, C., Rodríguez-Muela, N., Perez, C., Morales-Garcia, J. A., Reyes, J. A., Campillo, N. E., Perez-Castillo, A. M., Rubin, L. L., Timchenko, L., Gil, C., & Martinez, A. (2017). Journal of medicinal chemistry, 60, 4983–5001. https://doi.org/10.1021/acs.jmedchem.7b00395
T cells control the generation of nanomolar-affinity anti-glycan antibodies. Polonskaya, Z., Deng, S., Sarkar, A., Kain, L., Comellas-Aragones, M., McKay, C. S., Kaczanowska, K., Holt, M., McBride, R., Palomo, V., Self, K. M., Taylor, S., Irimia, A., Mehta, S. R., Dan, J. M., Brigger, M., Crotty, S., Schoenberger, S. P., Paulson, J. C., Wilson, I. A., … Teyton, L. (2017). The Journal of clinical investigation, 127(4), 1491–1504. https://doi.org/10.1172/JCI91192
Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Medina-Rodríguez, E. M., Bribián, A., Boyd, A., Palomo, V., Pastor, J., Lagares, A., Gil, C., Martínez, A., Williams, A., & de Castro, F. (2017). Scientific reports, 7, 43545. https://doi.org/10.1038/srep43545
The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Pérez-Domper, P., Palomo, V., Gradari, S., Gil, C., de Ceballos, M. L., Martínez, A., & Trejo, J. L. (2017). Neuropharmacology, 116, 174–187. https://doi.org/10.1016/j.neuropharm.2016.12.019
Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Palomo, V., & Martinez, A. (2017). Expert opinion on therapeutic patents, 27, 657–666. https://doi.org/10.1080/13543776.2017.1259412
2016
Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. de Munck, E., Palomo, V., Muñoz-Sáez, E., Perez, D. I., Gómez-Miguel, B., Solas, M. T., Gil, C., Martínez, A., & Arahuetes, R. M. (2016). PloS one, 11, e0162723. https://doi.org/10.1371/journal.pone.0162723
3,4-Dihydroxyphenylalanine Peptides as Nonperturbative Quantum Dot Sensors of Aminopeptidase. Palomo, V., Díaz, S. A., Stewart, M. H., Susumu, K., Medintz, I. L., & Dawson, P. E. (2016). ACS nano, 10, 6090–6099. https://doi.org/10.1021/acsnano.6b01682
2015
Photoligation of an amphiphilic polymer with mixed coordination provides compact and reactive quantum dots. Wang, W., Kapur, A., Ji, X., Safi, M., Palui, G., Palomo, V., Dawson, P. E., & Mattoussi, H. (2015). Journal of the American Chemical Society, 137, 5438–5451. https://doi.org/10.1021/jacs.5b00671
Delivery and tracking of quantum dot peptide bioconjugates in an intact developing avian brain. Agarwal, R., Domowicz, M. S., Schwartz, N. B., Henry, J., Medintz, I., Delehanty, J. B., Stewart, M. H., Susumu, K., Huston, A. L., Deschamps, J. R., Dawson, P. E., Palomo, V., & Dawson, G. (2015). ACS chemical neuroscience, 6, 494–504. https://doi.org/10.1021/acschemneuro.5b00022
UV and sunlight driven photoligation of quantum dots: understanding the photochemical transformation of the ligands. Aldeek, F., Hawkins, D., Palomo, V., Safi, M., Palui, G., Dawson, P. E., Alabugin, I., & Mattoussi, H. (2015). Journal of the American Chemical Society, 137, 2704–2714. https://doi.org/10.1021/ja512802x
2014
Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. Morales-Garcia, J. A., Palomo, V., Redondo, M., Alonso-Gil, S., Gil, C., Martinez, A., & Perez-Castillo, A. (2014). ACS chemical neuroscience, 5, 194–204. https://doi.org/10.1021/cn400166d
Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Franklin, A. V., King, M. K., Palomo, V., Martinez, A., McMahon, L. L., & Jope, R. S. (2014). Biological psychiatry, 75, 198–206. https://doi.org/10.1016/j.biopsych.2013.08.003
2013
Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. Beurel, E., Kaidanovich-Beilin, O., Yeh, W. I., Song, L., Palomo, V., Michalek, S. M., Woodgett, J. R., Harrington, L. E., Eldar-Finkelman, H., Martinez, A., & Jope, R. S. (2013). Journal of immunology, 190, 5000–5011. https://doi.org/10.4049/jimmunol.1203057
2012
Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. Morales-Garcia, J. A., Luna-Medina, R., Alonso-Gil, S., Sanz-Sancristobal, M., Palomo, V., Gil, C., Santos, A., Martinez, A., & Perez-Castillo, A. (2012). ACS chemical neuroscience, 3, 963–971. https://doi.org/10.1021/cn300110c
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice. Redondo, M., Palomo, V., Brea, J., Pérez, D. I., Martín-Álvarez, R., Pérez, C., Paúl-Fernández, N., Conde, S., Cadavid, M. I., Loza, M. I., Mengod, G., Martínez, A., Gil, C., & Campillo, N. E. (2012). ACS chemical neuroscience, 3, 793–803. https://doi.org/10.1021/cn300105c
The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. Susín, C., Morales-Garcia, J. A., Aguilar-Morante, D., Palomo, V., Sanz-Sancristobal, M., Alonso-Gil, S., Gil, C., Santos, A., Martinez, A., & Perez-Castillo, A. (2012). Journal of neurochemistry, 122, 1193–1202. https://doi.org/10.1111/j.1471-4159.2012.07866.x
Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Lipina, T. V., Palomo, V., Gil, C., Martinez, A., & Roder, J. C. (2013). Neuropharmacology, 64, 205–214. https://doi.org/10.1016/j.neuropharm.2012.06.032
5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3β (GSK-3β) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin. Pérez, D. I., Pistolozzi, M., Palomo, V., Redondo, M., Fortugno, C., Gil, C., Felix, G., Martinez, A., & Bertucci, C. (2012). European journal of pharmaceutical sciences, 45, 677–684. https://doi.org/10.1016/j.ejps.2012.01.007
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. Palomo, V., Perez, D. I., Perez, C., Morales-Garcia, J. A., Soteras, I., Alonso-Gil, S., Encinas, A., Castro, A., Campillo, N. E., Perez-Castillo, A., Gil, C., & Martinez, A. (2012). Journal of medicinal chemistry, 55, 1645–1661. https://doi.org/10.1021/jm201463v
2011
Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities.Palomo, V., Soteras, I., Perez, D. I., Perez, C., Gil, C., Campillo, N. E., & Martinez, A. (2011). Journal of medicinal chemistry, 54, 8461–8470. https://doi.org/10.1021/jm200996g
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. Perez, D. I., Palomo, V., Pérez, C., Gil, C., Dans, P. D., Luque, F. J., Conde, S., & Martínez, A. (2011). Journal of medicinal chemistry, 54, 4042–4056. https://doi.org/10.1021/jm1016279
PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury. Paterniti, I., Mazzon, E., Gil, C., Impellizzeri, D., Palomo, V., Redondo, M., Perez, D. I., Esposito, E., Martinez, A., & Cuzzocrea, S. (2011). PloS one, 6, e15937. https://doi.org/10.1371/journal.pone.0015937